Release Date: 2024-09-18

Idiopathic Pulmonary Fibrosis

Cüneyt Tetikkurt (Author)

Release Date: 2024-09-18

Idiopathic Pulmonary Fibrosis is a groundbreaking book designed to provide pulmonary and internal medicine clinicians and healthcare professionals with a comprehensive understanding of this complex lung disease. Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease characterized by the scarring of lung tissue, leading to difficulty breathing and decreased lung function. Despite its [...]

Be the first to leave a review.
Media Type

Out of stock

Buy from

Price may vary by retailers

Work TypeMonograph
Internal ReferenceNBL76
Edition1
DOIhttps://doi.org/10.69860/nobel.9786053359517
ISBN978-605-335-951-7 (PAPERBACK)
Page Count152
Print Lenght152
PlaceIstanbul
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

BICMJL
BISACMED079000
THEMAMJL

Idiopathic Pulmonary Fibrosis is a groundbreaking book designed to provide pulmonary and internal medicine clinicians and healthcare professionals with a comprehensive understanding of this complex lung disease. Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease characterized by the scarring of lung tissue, leading to difficulty breathing and decreased lung function. Despite its significant impact on quality of life and prognosis, idiopathic pulmonary fibrosis remains poorly understood by many. In this book, clinicians will embark on a journey through the intricacies of idiopathic pulmonary fibrosis from its underlying causes to its clinical manifestations, diagnosis, treatment options, complications, and treatment options in special conditions. Written in accessible language, the book aims to demystify the disease while empowering individuals affected by idiopathic pulmonary fibrosis to actively participate in their care journey.
Key topics covered in idiopathic pulmonary fibrosis include Pathophysiology and Etiology: Explore the underlying mechanisms driving the development and progression of IPF, including genetic predispositions, environmental factors, and immune dysregulation. Clinical Presentation: Learn to recognize the signs and symptoms of idiopathic pulmonary fibrosis, including progressive dyspnea, dry cough, fatigue, and unexplained weight loss, and understand the importance of early detection and timely intervention.
Diagnostic Approaches: gain insights into the various diagnostic modalities used to confirm idiopathic pulmonary fibrosis, including high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), bronchoscopy, and surgical lung biopsy, as well as the importance of multidisciplinary collaboration in reaching an accurate diagnosis.
Treatment Strategies: explore the current standards of care for idiopathic pulmonary fibrosis, including pharmacological interventions such as antifibrotic medications and immunosuppressive therapies, as well as non-pharmacological approaches such as pulmonary rehabilitation, supplemental oxygen therapy, and lung transplantation. Disease Management: Receive practical guidance on managing the symptoms and complications of IPF, optimizing respiratory function, promoting physical and emotional well-being, and navigating the challenges of living with a chronic lung condition. The chapter idippathic pulmonary fibrosis in special conditions comprises the treatment approaches in the elderley and the pregnant patinets.

1. Introduction
2. Definition and Overview
3. Epidemiology
4. Etiology and Risk Factors
5. Pathogenesis
6. Pathology
7. Genetic Phenotypes of Idiopathic Pulmonary Fibrosis
8. Clinical Manifestations
9. Physical Examination
10. Radiological Features
11. Laboratory and Pulmonary Function Tests
12. Diagnosis
13. Pharmacological Treatment
14. Non-Pharmacological Treatment
15. Complications and Prognosis
16. Special Considerations in Idiopathic Pulmonary Fibrosis

    Cuneyt Tetikkurt (Author)
    Department of Pulmonary Pulmonary Diseases, Istanbul Cerrahpasa University
    https://orcid.org/0000-0002-4122-2908
    3Doctor of Medicine (MD): Istanbul Medical Faculty, Istanbul University, 1984 Residency in Internal Medicine: Pulmonary Diseases Department, Istanbul Medical Faculty, Istanbul University, 1990 Fellowship in Pulmonary Medicine: Pulmonary Diseases Department, Istanbul Medical Faculty, Istanbul University, 1990-1993 Academic career: Associate Professor 1993, Professor 2000 Professional Memberships: American Thoracic Society (ATS); European Respiratory Society (ERS) Publications: has a toral of 175 publications including 21 national papers, 88 international papers, 20 Turkish books and 5 English books

    • Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.

    • American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Ma JRespir Crit Care Med 2000161(2Pt1):646-664

    • Raghu, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011; 183(6): 788–824.

    • Collard HR, Richeldi L (ed). Interstitial lung diseases. Philadelphia. Elsevier; 2018.

    • Brown KK, Wsigriss JJ (ed). Idiopathic pulmonary fibrosis. St Louis. Elsevier; 2019.

    • Raghu G, Rochwerg B, Zhang Y, et al. (July 2015). "An Official ATS/ ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline". American Journal of Respiratory and Critical Care Medicine. 192 (2): e3–19.

    • Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013;188(6):733–748.

    • Sverzellati N. Respir Res 2013; 14(Suppl 1): S3.

    • Steele MP, Peljto AL, Mathai SK, et al. Incidence and Progression of Fibrotic Lung Disease in an At-Risk Cohort. Am J Respir Crit Care Med 2023;207:5,587–593.

    • Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of Idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137(1):129-37.

    • Ohno S, Nakaya T, Bando M, Sugiyama Y. Idiopathic pulmonary fibrosis--results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008;13(6):926-928.

    • Meyer KC, Nathan SD (eds).Idiopathic pulmonary fibrosis, A Comphrensive Clinical Guide. Humana Press. Springer 2104.

    • Hamman L, Rich AR. Fulminating Diffuse Interstitial Fibrosis of the Lungs. Trans Am Clin Climatol Assoc 1935;51:154-163.

    • Liebow AA. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975;8:1-31.

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#8

    • Nakamura H, Aoshiba K (eds). Idiopathic pulmonary fibrosis. Advances in Diagnostic Tools and Disease Management. Tokyo. Springer. 2016.

    • Figueroa CGS, Carrillo G, Pérez-Padilla R, et al. Risk factors for Idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med 2010;104(2):305-209.

    • Wolters PJ, Collard HR, and Jones KD. Pathogenesis of Idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157–179.

    • https://respiratory-research.biomedcentral.com/articles/10.1186/ s12931-018-0730-2

    • https://www.frontiersin.org/journals/pharmacology/articles/10.3389/ fphar.2021.797292/full

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#1

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#2

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#4

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#5

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#6

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#11

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#12

    • https://reference.medscape.com/slideshow/ idiopathic-pulmonary-fibrosis-6009313#14

    • https://emedicine.medscape.com/article/301226-overview

    • Pergolizzi JV , LeQuang JA, Varrassi M, et al. What Do We Need to Know About Rising Rates of Idiopathic pulmonary fibrosis? A Narrative Review and Update. Adv Ther 2023; 40(4): 1334–1346

    • Richeldi L, Collard H, Jones M. Idiopathic pulmonary fibrosis. Lancet 2017;389(10082):1941–1952.

    • Maher T, Bendstrup E, Dron L, et al. Global incidence and prevalence of Idiopathic pulmonary fibrosis. Respir Res 2021;22(1):197.

    • American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165(2):277–304.

    • Raghu G, Weycker D, Edelsberg J, Bradford W, Oster G. Incidence and prevalence of Idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174(7):810–816.

    • Strongman H, Kausar I, Maher T. Incidence, prevalence, and survival of patients with Idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35(5):724–736.

    • Meiners S, Eickelberg O, Königshoff M. Hallmarks of the ageing lung. Eur Respir J 2015;45(3):807–827.

    • Zaman T and Lee JS. Risk factors for the development of Idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep 2018; 7(4): 118–125.

    • Lederer DJ, Martinez FJ: Idiopathic pulmonary fibrosis. N Engl J Med 2018, 378(19):1811–1823.

    • King TE Jr., Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807):1949–1961.

    • Ranzieri S, Magrini EI, Mozzoni P, et al. Idiopathic pulmonary fibrosis and occupational risk factors. Med Lav 2019;110(6):407-36

    • Kawbata Y. What is acute exacerbation of chronic interstitial pneumonia? Mod Physician 1994;14:117-120.

    • Mandal RV, Mark EJ, Kradin RL. Organizing pneumonia and pulmonary lymphatic architecture in diffuse alveolar damage. Hum Pathol 2008;39(8):1234-1238.

    • Parambil JG, Myers JL, Ryu J. Histopathologic features and outcome of patients with acute exacerbations of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:3310-3315.

    • Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994;18(2):136-147.

    • https://www.msdmanuals.com/professional/cardiovascular-disorders/heart-failure/cor-pulmonale#Pathophysiology_v936487

    • https://www.msdmanuals.com/home/multimedia/table/ recognizing-finger-clubbing

    • https://www.dailymail.co.uk/health/article-7727429/Simple-fingertest-reveal-cancer.html

    • hhttps://www.researchgate.net/figure/Nail-clubbing-Obliteration-ofhyponychial-angle-Nail-fold-angle-180-0-and_fig3_334697259ttps:// www.facebook.com/hijamatherapycliniccotabato/photos/a.63844026 2934891/2221948964584005/?type=3

    • Mathieson JR, Mayo JR, Staples CA, Müller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology1989;171(1):111-116.

    • Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124(4):1215-1223

    • Hansel DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246(3):697-722.

    • Jacob J, Hansell DM. HRCT of fibrosing lung disease. Respirology 2015;20(6):859-872.

    • Kim DS, Park JH, Park BK, et al. Acute exacerbation of Idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27(1):143-150.

    • Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of Idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128(5):3310-3315. Mayo Clin Proc 2002;77(8):763-770.

    • Kishia K, Hommab S, Kurosaki A, et al. High-resolution computed tomography findings of lung cancer associated with Idiopathic pulmonary fibrosis. Journal of Computer Assisted Tomography 2006; 30(1):95-99.

    • Oh SY, Kim MiY, Kim J-E, et al. Evolving Early Lung Cancers Detected During Follow-Up of Idiopathic Interstitial Pneumonia: Serial

    • Lee HJ, Im JG, Ahn JM, Yeon KM. Lung cancer in patients with Idiopathic pulmonary fibrosis: CT findings. J Comput Assist Tomogr 1996;20(6):979-982.

    • Tan RT, Kuzo R, Goodman LR, et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest 1998;113(5):1250-1256.

    • Shin S, King CS, Puri N, et al.Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016;47(5):1445-1451

    • Cottin V, Nunes H, Brillet P-Y, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26(4):586-593.

    • Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012;141(1):222-231.

    • https://ashevillebeecharmer.com/honey-tips/honeycomb-edible/

    • https://radiopaedia.org/articles/honeycombing-lungs

    • 64. https://emedicine.medscape.com/article/2078590-overview

    • http://www.svuhradiology.ie/case-study/pulmonary-fibrosis/

    • https://radiopaedia.org/cases/pulmonary-fibrosis-severe-2

    • https://www.researchgate.net/figure/Idiopathic-pulmonary-fibrosis-HRCT-at-the-level-of-the-lower-lobes-shows-a-subpleural_ fig5_233941472

    • https://www.pulmonologyadvisor.com/home/topics/restrictive-lungdisease/multimorbidities-in-idiopathic-pulmonary-fibrosis-may-relate-to-4-phenotype-groups/

    • https://emedicine.medscape.com/article/301226-workup#c4

    • Martinez FJ and Flaherty K. Pulmonary Function Testing in Idiopathic Interstitial Pneumonias. Proc Am Thorac Soc 2006;3(4): 315–321.

    • Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA, Ackerson L, Schwarz MI, King TE. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;151:1180–1188.

    • Doherty M, Pearson M, O'Grady E, Pellegrini V, Calverley P. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997;52:998–1002

    • Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997;111:51–57.

    • Robertson H. Clinical application of pulmonary function and exercise tests in the management of patients with interstitial lung disease. Semin Respir Crit Care Med 1994;15:1–9.

    • Lama V, Flaherty K, Toews G, Colby T, Travis W, Long Q, Murray S, Kazerooni E, Gross B, Lynch J III, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084–1090.

    • Risk C, Epler G, Gaensler E. Exercise alveolar–arterial oxygen pressure difference in interstitial lung disease. Chest 1984;85:69–74.

    • Jezek V, Fucik J, Michaljanic A, Jeskova L. The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopathol Respir 1980;16:711–720.

    • Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998;113:396–400.

    • Egan J, Martinez F, Wells A, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005;60:270–273.

    • Jegal U, Kim D, Shim T, Lim C, Lee S, Koh Y, Kim W, Kim W, Lee J, Travis W, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639–644.

    • Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531–537.

    • https://link.springer.com/chapter/10.1007/978-3-319-99975-3_5

    • Chiba H and Takahashi H. Specific Serum Markers of IPF. Idiopathic Pulmonary Fibrosis. 2015;3: 61–76.

    • Jee AS, Sahhar J, Youssef P. Et al. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease – frontiers and horizons. Pharmacology & Therapeutics 2019:Volume 202:40-52.

    • Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11(2):164-168.

    • Song JW, Do KH, Jang SJ, Colby TV, et al. Blood biomarkers MMP7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013;143(5):1422-1429.

    • Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013;188(6):733-748.

    • Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest 1999;116(5):1168-1174.

    • Collard HR, Richeldi L (eds). Interstitial Lung Disease. Philadelphia. Elsevier. 2018.

    • Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. European Respiratory Journal 1999,14(4):735-737

    • Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(8):717-723.

    • Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(11):1043-1047.

    • Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016;193(7):745-752.

    • Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline. Thorax 2008:63 Suppl 5:v1-58.

    • Chechani V, Landreneau RJ, Shaikh SS. Open lung biopsy for diffuse infiltrative lung disease.Ann Thorac Surg 1992;54(2):296-300.

    • Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007;83(3):1140-1144.

    • Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. European Respiratory Journal 2007;30:715-721.

    • Nina MP, Lederer D, Borczuk AC, et al. Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest 2007;132(3):998-1006.

    • Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170(4):360-365. European Respiratory Journal 2010 36: 819-825.

    • Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010;36(4):819-825

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    reviews

    Reviews

    There are no reviews yet.

    Be the first to review “Idiopathic Pulmonary Fibrosis”

    Your email address will not be published. Required fields are marked *

    related products

    Categories:

    Share This Book!